Daniel Maslyar
Impact in
- Oncology top 5%
- CAR-T cell therapy research
- HER2/EGFR in Cancer Research
- Biotechnology top 5%
Papers in
-
- Prostate Cancer Treatment and Research 10
- Lung Cancer Treatments and Mutations 4
- Advanced Breast Cancer Therapies 4
- Oncology 21
- Cancer Treatment and Pharmacology 9
- Co-authors
- Luca Comai (1 shared paper)Paul Moran (1 shared paper)Peter K. Vogt (3 shared papers)Robert Dietrich (4 shared papers)John J. Harada (4 shared papers)Joel Desharnais (1 shared paper)Dale L. Boger (1 shared paper)Thorsten Berg (1 shared paper)
- Journals
- Journal of Clinical Oncology (14 papers)Annals of Oncology (5 papers)The Plant Cell (4 papers)Cancer Research (3 papers)Molecular Therapy (2 papers)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Daniel Maslyar
44 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 90
- Oncology 616
- Biotechnology 171
- Molecular Biology 864
- Pulmonary and Respiratory Medicine 381
- Cancer Research 173
Countries citing papers authored by Daniel Maslyar
This map shows the geographic impact of Daniel Maslyar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Maslyar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Maslyar more than expected).
Fields of papers citing papers by Daniel Maslyar
This network shows the impact of papers produced by Daniel Maslyar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Maslyar. The network helps show where Daniel Maslyar may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Maslyar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 44 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2002 | 261 | |
| 2 | 2018 | 227 | |
| 3 | 2012 | 191 | |
| 4 | 1990 | 145 | |
| 5 | 1989 | 111 | |
| 6 | 2016 | 85 | |
| 7 | 2009 | 81 | |
| 8 | 2015 | 77 | |
| 9 | 2019 | 59 | |
| 10 | 1989 | 48 | |
| 11 | 2016 | 40 | |
| 12 | 2018 | 38 | |
| 13 | 2002 | 27 | |
| 14 | 2020 | 26 | |
| 15 | 2014 | 22 | |
| 16 | 2001 | 20 | |
| 17 | 2018 | 20 | |
| 18 | 2010 | 17 | |
| 19 | 2016 | 16 | |
| 20 | 2014 | 15 |
About Daniel Maslyar
Daniel Maslyar is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Molecular Biology, Biotechnology and Reproductive Medicine, having authored 44 papers that have together received 1.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (10 papers), Cancer Treatment and Pharmacology (9 papers), PI3K/AKT/mTOR signaling in cancer (8 papers), Ovarian cancer diagnosis and treatment (6 papers), Cancer Research and Treatments (5 papers), Photosynthetic Processes and Mechanisms (4 papers), Lung Cancer Treatments and Mutations (4 papers) and Advanced Breast Cancer Therapies (4 papers). The work is most often cited by research in Oncology (616 citations), Biotechnology (171 citations), Molecular Biology (864 citations), Pulmonary and Respiratory Medicine (381 citations) and Cancer Research (173 citations). Daniel Maslyar has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Luca Comai, Paul Moran, Peter K. Vogt, Robert Dietrich, John J. Harada, Joel Desharnais, Dale L. Boger, Thorsten Berg, Joel Goldberg and Steven B. Cohen. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The Plant Cell, Cancer Research and Molecular Therapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.